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ABSTRACT

The aim of this study was to evaluate the pattern of Adverse Drug Reactions (ADRs) related to antineoplastic and
immunomodulating agents in Egypt. We extracted all ADR reports of antineoplastic and immunomodulating agents
(Anatomical Therapeutic Chemical (ATC) code L) that were reported to Egyptian Pharmaceutical Vigilance Center (EPVC)
from January 2011 to December 2015 using VigiLyze TM. Afterwards, these reports were analyzed and categorized by
age, sex, reporter qualification, seriousness, type of ADRs, medications, indications of use and causality. During the study
period, 1905 reports related to antineoplastic and immunomodulating agents were received; 44.6% of which were reported
by consumers and 56.8% by health care professionals. ADRs were serious in 13.3% and 65.1% of the cases reported by
consumers and healthcare professionals, respectively. Approximately half (52.5%) of the reported ADRs occurred in females
and only 8.4% occurred in children. Half of the reported ADRs (51.5%)  occurred in middle aged group (45- 64 years).
The most reported classes at the therapeutic level were immunostimulants (ATC code L03) and antineoplastic agents (ATC
code L01). The most frequently reported medication was peg-interferon alfa-2a. The majority of ADRs were of the type
"general disorders and administration site conditions" and "gastrointestinal disorders". In conclusion, ADRs caused by
immunostimulants especially interferons have higher tendency to be reported in Egypt especially in the middle-aged group.
Additionally, the study has shown that serious ADRs of antineoplastic and immunomodulating agents were more likely to be
reported by healthcare professionals rather than consumers.
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1. INTRODUCTION

scope of PV has also been expanded to include problems
related to medication use like medication errors, off-label
use, misuse and abuse[3]. The main purposes of PV are to
ensure the safe use of medicines and to improve public
safety[3].

Adverse Drug Reactions (ADRs) are undesirable events
resulting from taking a medication. The World Health
Organization (WHO) defines ADR as any response to a
drug which is noxious and unintended, and which occurs at
doses normally used in human beings for the prophylaxis,
diagnosis, or therapy of disease, or for the modifications
of physiological function[1]. In addition to their impact on
population's health, ADRs possess a significant economic
burden on healthcare system.

Before any medication is launched to the market, it
undergoes several phases of clinical trials to determine
the safety and the efficacy of the drug[4]. However, these
phases are usually not sufficient to detect all ADRs as
clinical trials are conducted on a small number of patients
for a short period with strict inclusion and exclusion criteria
which excludes special populations like elderly people
who already have a high prevalence of cancer diseases[4].
Consequently, this group is underrepresented in cancer
clinical trials[4].

Antineoplastic and immunomodulating agents are used
for treatment of different types of neoplasms and immune
diseases[2]. High toxicity of these medications predispose
patients to serious ADRs since the toxicity of anticancer
medications is not limited to malignant cells but it can also
affect normal cells[2].
The science of recognizing unidentified ADRs is called
pharmacovigilance (PV). As defined by WHO, PV is the
science and activities relating to the detection, assessment,
understanding and prevention of adverse drug effects or
any other possible medication-related problems[3]. The

Spontaneous reporting is the main source of information
for pharmacovigilance[5]. It is defined as voluntary submitting
of ADR reports to national pharmacovigilance centers[5]. The
main obstacle that confronts spontaneous reporting systems
is under-reporting[5]. It causes delay in detecting ADRs and
taking regulatory actions towards them[5]. Other limitations
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of spontaneous reporting include biases, delays in adverse
events recognition and report quality[5].

includes one or more ADR that is suspected to be caused
by one or more drugs.

United Kingdom took the lead in making voluntary
reporting system when the Yellow Card was launched
by Committee on Safety of Medicines (CSM) in 1964
after the thalidomide tragedy[6]. Yellow Card is a scheme
for gathering information about Individual Case Safety
Reports (ICSRs). The yellow card has been applied in
many countries worldwide including Egypt.

Regarding age, reports were classified into 5 groups as
follow: 0-18 years old, 18-44 years old, 45-64 years old, 6574 years old and more than 75 years old. This classification
is based on the WHO classification and is already used by
VigiLyze TM[11].
Serious ADRs were classified according to International
Conference on Harmonization (ICH) definition into fatal,
life-threatening, requiring hospitalization or prolongation
of existing hospitalization, resulting in persistent or
significant disability or incapacity, a congenital anomaly/
birth defect and other medically important conditions[12].

Egypt joined the WHO Programme for International
Drug Monitoring in 2001 but the Egyptian Pharmaceutical
Vigilance Center (EPVC) has been established at the
Central Administration of Pharmaceutical Affairs (CAPA)
in December 2009[7]. The main role of EPVC is collecting
reports submitted by physicians, pharmacists, other
health care professionals and consumers using yellow
cards as well as Council of International Organizations
for Medical Sciences (CIOMs) forms submitted by
Marketing Authorization Holders (MAHs)[8]. Yellow
cards are available at EPVC website to be completed
online or downloaded. They are also available at the
pharmacovigilance coordinator in each hospital. Reports
then can be received online, by fax, by e-mail, by hand or
by phone.

Suspected medications were classified according to
active ingredients using ATC classification up to the fourth
level (chemical subgroup)[13]. Clinical manifestations
were defined based on Medical Dictionary for Regulatory
Activities (MedDRA) term using MedDRA Version 19.1
at SOC level[14].
Causality of ADRs was assessed using the World
Health Organization-Uppsala Monitoring Centre (WHOUMC) assessment scale into certain, probable/likely,
possible, unlikely, conditional/unclassified or unassessable/
unclassifiable[15].

The current study investigated the pattern of ADR
reports on antineoplastic and immunomodulating agents
received by EPVC during the first five years of its
launching.

3. STATISTICAL ANALYSIS
Data analysis was performed using SPSS version 22
(IBM Inc., Chicago, USA). Percentages and frequencies
were calculated. Chi-square was used to test the association
between the reporter qualification and the report's
seriousness[16].

2. MATERIAL AND METHODS
This is a descriptive retrospective study that
included all ADR reports related to antineoplastic and
immunomodulating medications (Anatomical Therapeutic
Chemical (ATC) code L) that were submitted to
EPVC between January 2011 and December 2015. All
spontaneous reports that complied with the validation
criteria (identifiable patient, identifiable reporter, at least
one ADR, at least one suspected drug) were collected. The
study protocol was approved by the Ethics Committee of
the Faculty of Pharmacy, Cairo University (Number of
approval: CL (1330)).

4. RESULTS
The EPVC received 7220 spontaneous ADR reports
from 2011 to 2015, 1905 reports of which contained
information about 5256 ADRs recorded for antineoplastic
and immunomodulating drugs.
Based on the 2nd level ATC classification, medicines
included in ADR reports were immunostimulants (ATC code
L03) (47.2% of suspected drugs) followed by antineoplastic
agents (ATC code L01) (43%), immunosuppressants (ATC
code L04) (8.2%) and endocrine therapy (ATC code L02)
(1.6%).

Spontaneous reports were characterized according
to the reporter qualification (physician, pharmacist,
other healthcare professional or consumer), patient's
age and sex, seriousness, ADRs classified by System
Organ Class (SOC), medicines, indication of use and
causality. Consumer is a person from general public who
is not healthcare professional such as patient or patient's
relative[9]. ADR data were extracted from VigiLyze TM
which is a web-based search and retrieval tool that provides
access to the global ICSR database (VigiBase) for all PV
staff members[10].

Regarding reporter’s qualification, 44.6% of reports
were received from consumers while 56.8% were reported
by health care professional (33.2% physicians, 14.7%
pharmacists and 8.9% other health care professionals).
Only 8.4% of ADR reports occurred in children (<18
years). Half of the reports were in older adults aged 45 to
64 years (51.5%) and 52.5% of ADR reports were reported
for women.

Each ADR report contains only one case and one
patient but it may be reported by one or more reporter and

Regarding seriousness, 43.3% of reports were serious
including 112 fatal cases. Only 13.3% of reports submitted
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by consumers were serious with 5 death reports while
65.1% of healthcare professional reports were serious
with 101 death reports. This association between reporter's

qualification and seriousness was statistically significant
(P< 0.05). Table 1 shows the correlation between reporter's
qualification and seriousness of reports.

Table 1: Association between type of reporter and seriousness of reports received by Egyptian Pharmaceutical Vigilance Center (EPVC) from
2011 to 2015
Seriousness

Type of reporter
Healthcare professional

Consumer

P-value (P<0.05)

Death

100 (95.2%)

5(4.8%)

0.000

Life-threatening

85 (97.7%)

2 (2.3%)

0.000

Caused/prolonged hospitalization

191 (86.8%)

29 (13.2%)

0.000

Disabling/incapacitating

35 (97.2%)

1 (2.8%)

0.000

Congenital anomaly/birth defect

1 (100%)

0 (0%)

1.000*

Other

362 (81%)

85 (19%)

0.000

333 (32.4%)

696 (67.6%)

0.000

Not serious

* Fisher’s Exact was used instead of Chi-square because one or more cells had expected count less than 5

Regarding fatal cases (n = 112), 60% were reported in
males, 67% (n=75) were reported by physicians and only
4.4% (n= 5) were submitted by consumers. The incidence
of fatal ADRs was highest common in the 45 to 64-year
age group (30%, n=34). The most frequently reported fatal
ADRs belonged to general disorders and administration site
conditions (18.6%) followed by gastrointestinal disorders
(10.2%) and blood and lymphatic system disorders (9.8%).

L01DB01) (10.7%, n=12) and docetaxel (ATC code
L01CD02) (8.9%, n=10).

The majority of fatal reports were related to
antineoplastic agents (L01) (75% of fatal reports) while
immunostimulants (L03) caused death in 11.6% of fatal
reports. Drugs associated with fatal reports were rituximab
(ATC code L01XC02) (12.5%, n=14), sorafenib (ATC
code L01XE05) (11.6%, n=13), doxorubicin (ATC code

Most of the reports related to immunostimulants were
non-serious reports unlike reports related to antineoplastic
agents which were serious in most of the cases (Table 2).
Based on WHO-UMC causality assessment scale, most of
ADRs (84.9%) were categorized as "possible". Only 0.5%
were classified as "conditional/ unclassified" (Table 3).

Peg-interferon alfa-2a (ATC code L03AB61) (n=
777) was the most frequently reported drug followed
by interferon beta-1a (ATC code L03AB07) (n= 233),
docetaxel (ATC code L01CD02) (n= 64) and rituximab
(ATC code L01XX21) (n= 63).
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Table 2: Distribution of adverse drug reactions reported to Egyptian Pharmaceutical Vigilance Center (EPVC) for antineoplastic and
immunomodulating agents by medication and seriousness 2011 to 2015.
Therapeutic group (ATC)

Antineoplastic agents (L01)

Chemical/therapeutic/ pharmacological subgroup pharmacological subgroup

N (ADRs)

N (serious ADRs)

Nitrogen mustard analogues

66

47

Other alkylating agents

12

9

Folic acid analogues

47

42

Purine analogues

22

18

Pyrimidine analogues

154

117

Vinca alkaloids and analogues

55

50

Podophyllotoxin derivatives

10

6

Taxanes

103

79

Other plant alkaloids and natural products

2

2

Actinomycines

10

9

Anthracyclines and related substances

87

65

Other cytotoxic antibiotics

7

4

Platinum compounds

112

95

Monoclonal Antibodies

122

79

Protein kinase inhibitors

125

71

Other antineoplastic agents

90

71

1024

764

Gonadotropin releasing hormone analogues

12

8

Total L01
Endocrine therapy (L02)

Anti-estrogens

6

1

Anti-androgens

4

0

Aromatase inhibitors

16

8

38

17

Colony stimulating factors

10

8

Interferons

1107

240

Other immunuostimulants

7

5

Total L02
Immunostimulants (L03)

Total L03

1124

253

Selective immunosuppressants

103

85

Tumor necrosis factor alfa inhibitors

46

21

Interleukin inhibitors

27

18

Calcineurin inhibitors

10

8

Immunosuppressants (L04)

10

7

Total L04

Other immunosuppressants

196

139

Total L

2382

1173

Hepatitis C Virus (HCV) accounted for 34.8% of
the indications for suspected drugs (n=831) followed by
multiple sclerosis (10%, n=240) and breast cancer (8.3%,
n=197) (Table 4).

Table 3: Causality of ADRs reported to Egyptian
Pharmaceutical Vigilance Center (EPVC) for antineoplastic and
immunomodulating agents: 2011 to 2015
Causality assessment

Percentage (%)

Certain

0.7%

Probable/likely

7.9%

Possible

84.9%

Unlikely

2.1%

Conditional/unclassified

0.5%

Unassessable/unclassifiable

3.9%

The most common ADR categories (according
to MedDRA classification) were "General disorders
and administration site conditions" (21.3% of ADRs),
"gastrointestinal disorders"(11.4%) and "nervous system
disorders" (10.6%) (Table 5). Based on reporter’s
qualification, the 2nd most common ADR category in
consumers’ reports was "gastrointestinal disorders". The
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2nd most common categories according to physicians and
pharmacists were "blood and lymphatic system disorders"
and "nervous system disorders", respectively.

Table 5: Adverse drug reactions reported to Egyptian
Pharmaceutical Vigilance Center (EPVC) for antineoplastic and
immunomodulating agents: 2011 to 2015

Table 4: Indications of antineoplastic and immunomodulating
agents reported to Egyptian Pharmaceutical Vigilance Center
(EPVC): 2011 to 2015
Indications

N (drugs)

Adverse drug reactions (SOC)

Frequency (%)

General disorders and
administration site conditions

1117 (21.25)

Gastrointestinal disorders

597 (11.36)

Nervous system disorders

557 (10.6)

Investigations

383 (7.3)

Skin and subcutaneous
tissue disorders

376 (7.15)

Blood and lymphatic
system disorders

327 (6.22)

Musculoskeletal and
connective tissue disorders

303 (5.76)

Respiratory thoracic and
mediastinal disorders

268 (5.1)

Injury, poisoning and
procedural complications

161 (3.06)

Psychiatric disorders

151 (2.87)

Hepatitis C

831

Multiple sclerosis

240

Breast cancer

197

Hepatocellular carcinoma

100

Rheumatoid arthritis

47

Lung cancer

44

Non-Hodgkin's lymphoma

43

Vascular disorders

151 (2.87)

Infections and infestations

145 (2.76)

Colorectal cancer

37

Metabolism and
nutrition disorders

141 (2.68)

Nodular lymphoma

33

Immune system disorders

115 (2.19)

Eye disorders

108 (2.05)

Acute lymphoblastic leukemia

32

Renal and urinary disorders

89 (1.69)

Soft tissue sarcoma

31

Cardiac disorders

59 (1.12)

Hepatobiliary disorders

52 (1)

Bladder cancer

27

Neoplasm benign malignant
and unspecified

Colon cancer

23

Reproductive system
and breast disorders

34 (0.65)

Renal transplant

21

Surgical and medical procedures

23 (0.44)

Ear and labyrinth disorders

20 (0.38)

Lymphoblastic lymphoma

20

Pregnancy puerperium and
perinatal conditions

18 (0.34)

Other indications (n<20)

448

Endocrine disorders

10 (0.19)

Social circumstances

10 (0.19)

Unknown

208

Congenital, familial and
genetic disorders

1 (0.02)

Total drugs

2382

Total ADRs

DISCUSSION

40 (0.76)

5256 (100)

possess toxicity towards normal tissues with high growth
fraction like gastrointestinal tract, bone marrow and hair
follicles[18].

To our knowledge, this is the first study to describe
spontaneous ADR reporting in Egypt. We targeted reports
of antineoplastic and immunomodulating medications as it
was noticed that these drugs had the highest reporting rate
in Egypt since establishment of EPVC till the end of 2015.

Cancer is considered to be a major health problem in
Egypt especially liver and breast cancer[19]. It is one of the
most frequently leading causes of death worldwide and the
third cause in Egypt[20]. Liver is one of the most common
cancer sites in Egypt due to high prevalence of HCV as
Egypt has the highest prevalence of HCV globally[19].

Based on previous studies, antineoplastic agents and
immunomodulators are the most frequently associated
medications with causing ADRs as most of drugs in this
class have narrow therapeutic index[17]. It is well known
that chemotherapeutic agents' mechanism of actions
is dependent on their cytotoxic activity on rapidly
proliferating cells[18]. Consequently, chemotherapy also

Our study identified the pattern of ADRs caused by
antineoplastic and immunomodulating drugs reported to
EPVC database. We found that the frequency of ADRs was
higher in females than males. These results are consistent
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with a European study done on antineoplastic and
immunomodulators ADRs reported by consumers[21]. On
the contrary, Whalang et al. showed in their study that ADRs
are more common in male population[22]. The dominance
of female reports can be explained by gender differences
in the anatomical and physiological features such as fat
composition and hormonal changes[23]. These differences
might affect the pharmacokinetics and pharmacodynamics
of medications[23]. Furthermore, female patients have higher
drug utilization and medical consultation rates than males.
High prevalence of breast cancer among Egyptian female
patients may have contributed to their high reporting rate
of antineoplastic ADRs[19].

Gouda et. al.,

no certain ADRs[27]. Different results were found in other
studies carried out in South India[28]. The most common
causality assessment of ADRs in this study was probable
followed by possible[28]. The small percentage of "certain"
ADRs in our results is not surprising as the "certain"
causal relationship between a medication and an ADR is
difficult to establish, we have to get information about the
incidence of ADR after reintroducing the medication "rechallenge"[15]. This is considered unethical and inapplicable
in case of serious ADRs. As a result, lack of re-challenge
information makes “possible” the utmost grade that can be
assessed. Causality of some ADRs were "unassessable"
due to insufficient or contradictory information collected
about them.

The majority of ADRs were found in older adults (45-64
years) which is similar to what has been reported in a prior
Bangladesh study. In that study, ADRs of antineoplastic
medications mostly occurred in the age group (41-50
years)[24]. These findings could be attributed to the fact that
this age group usually have multiple comorbidities such
as diabetes, hypertension and other diseases which make
them consume more medications and subsequently more
prone to have ADRs.

In our study, general disorders and administration site
conditions were the most commonly reported SOC from
antineoplastic and immunomodulating drugs followed by
gastrointestinal disorders and nervous system disorders
and the most common ADR was fatigue. These findings
are in concordance with what have been reported
in previous studies. In a European study which was
conducted on consumers' reports of antineoplastic and
immunomodulating drugs, general disorders were the most
frequently reported ADRs in the study population followed
by skin and subcutaneous disorders and infections and
infestations[21]. Another study conducted in an Indian
hospital showed that gastrointestinal disorders was the most
frequently reported SOC from antineoplastic medications
followed by blood and lymphatic system disorders and the
most common ADR was vomiting[29].

Our study showed that consumers reported a
large number of ADR reports for antineoplastic and
immunomodulating agents (44.6%). This finding was
surprising since PVC reporting in general is relatively new
to Egypt. A British study in 2010 showed that low percent
of antineoplastic and immunomodulating agents reports
were reported by patients[25], even though Yellow Cards
were introduce in the United Kingdom in 1964. This finding
might be partially explained by the pattern of the EPVC
awareness campaigns from 2011-2015. EPVC team has
organized regular visits to hospitals to enhance the patients'
awareness of PV using different educational tools such as
posters and flyers. These tools have been distributed in the
patients' waiting areas of different hospitals with different
specialties. We found that oncology hospitals were among
the top five hospitals that had PV awareness visits from
2011 to 2015. Further studies need to investigate consumer
awareness of spontaneous reporting in Egypt.

Immunostimulants were responsible for the majority
of the ADRs especially peginterferon alfa-2a and
Interferon beta-1a followed by antineoplastic agents and
immunosuppressants. Conversely, immunosuppressants
had the largest share in Aagaard et al. study followed by
immunostimulants and antineoplastic agents[21]. In other
study by Schwartzberg et al. immunosuppressants were
observed also to be the most commonly reported class[30].
Previous studies have showed that Interferon beta has
better safety profile than Interferon alpha in treatment of
chronic hepatitis C[31]. This finding is in concordance with
the use of peginterferon alfa-2a in Egypt.

A small percentage of consumer reports were considered
serious. Similar results were observed by Aagaard et
al.[21]. We found a statistically significant difference in the
percentage of serious ADRs reported by consumers versus
health care professionals. This could be explained by the
fact that patients with serious ADRs would first seek the
help of healthcare professionals whom then would initiate
ADRs reporting rather than initiating a report themselves.
In contrast, patients might report non-serious ADRs.
Further analysis of non-serious ADRs is required since
consumers and healthcare professionals may have different
perception of seriousness[26].

Egypt has the highest HCV epidemic in the world. In
2015, in the less than 60-year age group, around 3.7 million
Egyptian citizens had positive HCV RNA[32]. From 2007
to 2014, peginterferon and ribavirin were the standard of
care for HCV in Egypt. More than 360,000 patients were
treated with this regimen during this time period[33]. In
our study, we found that patients treated for HCV had the
highest reporting share of ADRs.
Among cancer patients in our study, breast cancer
patients were the most common to experience ADRs.
Breast cancer is the most frequent cancer in Egyptian
female patients which explains our findings[19]. This is
similar to a study conducted in a tertiary care hospital in
South India to examine the adverse effects of anticancer

Regarding causality, most ADRs were classified
as possible with a low percentage of certain cases. This
finding is similar to a study conducted by Joshi et al. which
showed that the causality of most ADRs was possible with
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medications[34]. On the other hand, Mallik et al. showed
that patients with lung cancer had the highest ADRs share
in their study in a Nepalese hospital[35].
In spite that this study is the first to examine spontaneous
ADR reporting in Egypt, the study had several limitations.
First, this study was performed retrospectively therefore it
was not possible to access the original reports and missing
data was not recoverable. The fact that consumer reports
were very high could not be explained nor investigated as
well due to the retrospective nature. Second, underreporting
is a major limitation making our results non-generalizable.
One reason is that spontaneous reporting is relatively new
to Egypt. In addition, many reasons have been suggested
in the literature to explain under-reporting such as inability
to recognize ADRs, lack of time, fear of responsibility
and unawareness of reporting tools[5]. These reasons have
been clarified in an Egyptian study to investigate underreporting and the factors influencing ADR reporting[36].
5. CONCLUSION
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